5 Things to Know about Delta 8 Cannabis Products

Delta 8 Hospitalization CDC

 For DankeSuper, Delta 8 THC has been a tricky cannabinoid for us to place. On the one hand, our DSquared8 Gummies are incredibly popular. Our customers seem to really enjoy both the experience of the cannabinoids and product. At the same time, we’re offering a product that admittedly exists within a gray area, and there are reputation risks associated with dancing in a space without clear legal standing and regulation.

When we saw headlines regarding the Center for Disease Control & FDA warnings our eyes lit up in trepidation. “FDA, CDC issue delta-8 THC warnings after 100-plus end up in hospitals”, or Self Magazine “Delta-8 Cannabis Products Can Cause Scary Health Effects” we were concerned. Ultimately, the five key points made by the FDA on Delta 8 THC were logical considerations important in any psychoactive product that is not closely regulated.

 Here are the five the key points associated with the Food and Drug Administrations ‘Warning’:

1. Delta-8 THC has psychoactive and intoxicating effects.

We would like to make that abundantly clear without sounding like we are pushing “drugs” to get stoned. Most of our customers find it relaxing, fun, and a more mild experience than Delta-9 THC. If you never consume THC and have a strong adverse reaction historically, consume with an abundance of caution or not at all.

We dose our products so you feel an effect, but nowhere near a level that should get you dangerously high. We know people who have consumed over a dozen in an evening, didn’t feel great afterwards, and passed out for the night (without medical incident). One or two gummies providing a milder, relaxing experience relative to more psychoactive, high concentration Delta 9 THC products does not mean you can consume limitlessly without an adverse reaction.

2. Delta-8 THC products have not been evaluated or approved by the FDA for safe use and may be marketed in ways that put the public health at risk.

Brands that misrepresent cannabinoids by either mislabeling a delta-8 CBD or by not responsibly communicating Delta 8’s psychoactive effects are a danger to the cannabis industry and its consumers. The FDA has a responsibility to raise this concern, and it’s a valid one. It’s true for any industry that falls into an unregulated gray area. Agencies have not had sufficient time to evaluate Delta-8 THC’s benefits and/or risks, and lack of clear, consumer protecting regulation makes trust amongst Delta 8 products more difficult to navigate.
Our delta-8 is produced independently of our CBD rich hemp extract products. Both have certificates of analysis for cannabinoid profiles, residual solvents, mold or contamination. We do not have a large warning about Delta-8 psychoactive effects, but we only sell the product online (where we can clearly communicate) and should maybe revisit the possibility despite the unappealing aesthetic. Ultimately, consumers should select a brand they trust, and their due diligence should not be simply asking the gas station clerk, “So, it gets me high?”.
We’re working on improving our own communication in a way that’s navigable, informative, and non-overwhelming. If you ever have questions about Delta 8 or our products, reach out to us.

3.  Delta-8 THC products often involve use of potentially harmful chemicals to create the concentrations of delta-8 THC claimed in the marketplace. 

The way this statement is phrased makes it more intimidating than the message, and there are essentially two parts to it. The first is that processing CBD into Delta 8 THC can be unsafe without the right equipment, safety protocols, and protection. This is true for a number of processes in cannabis, it isn’t boat, our Delta-8 is not coming from the neighbor’s bath. There are risks if our Delta-8 were not produced by reputable, United States based, professional businesses that are highly transparent. Although, this is more a labor and sourcing concern than a direct risk to the consumer.
The second side of it is unsafe production of Delta-8 can absolutely harm the consumer, and it’s important to reiterate the importance of transparency and testing from the supplier. We would deeply appreciate it if a framework for our communication, testing, and labeling existed. It’s not the case, but we strive to establish trust with our customers with all our products. We take safety and testing very seriously, and take proactive approach in mitigating, if not eliminating, these types of risks.

4.   Delta-8 THC products should be kept out of the reach of children and pets.

This is an EXTREMELY obvious statement, but sadly as the next point exhibits one that clearly needs to be made. As a producer of Delta-8, it is not our intent to appeal to children, but our product is in a gummy / pate de fruit format that could have that effect. Keep it out of reach & sight of your children. I tell my daughter their adult vitamins that are not safe for kids, but she listens well in this context.
We’re working on a pet CBD pate de bone broth that will hopefully be appealing to your pet. A our gummies were not designed with this intention, but keep it on the counter (assuming they can’t reach) or even better put them back in safe place after consuming.

5.   The FDA has received adverse event reports involving delta-8 THC containing products

I actually felt relieved by these statistics in that they seem to reflect the other points made by the FDA rather than any underlying harmful indications around Delta-8 itself. Here are the statistics:
National poison control centers received 661 exposure cases of delta-8 THC products between January 2018 and July 31, 2021, 660 of which occurred between January 1, 2021, and July 31, 2021. Of the 661 exposure cases:
41% involved unintentional exposure to delta-8 THC and 77% of these unintentional exposures affected pediatric patients less than 18 years of age. 
39% involved pediatric patients less than 18 years of age
18% required hospitalizations, including children who required intensive care unit (ICU) admission following exposure to these products. 

This is not a safety claim regarding Delta-8 THC, but a several times more people die of COVID a day than the number of exposure cases of delta-8 THC products this entire year. The majority of those exposure cases were either minors who consumed their parents product or unintentional exposure. A child consuming a psychoactive is dangerous, and will likely generate a highly uncomfortable physiological reaction. People who consume a psychoactive without realizing it might understandably freak out. So, to be honest 660 for a 7 months period is not alarming in the slightest.

Ultimately, the headline embedded in the FDA’s hideous graphic design fails to reflect the valid points raised to the public. The headlines points were balanced statements that achieve a certain degree of sensationalist flair through the omission of details which the FDA goes on to explain. Out of all the scares that could occur in minor cannabinoids, this one appears minor and transient.

Older Post Newer Post

  • Typo in section 4: “their” should read “they’re” as in “they are.” No need to publish this comment. Just trying to help as spelling & grammar errors sometimes erode credibility. (BTW, I can only handle a half or quarter Delta-8 gummy & I’ve been enjoying moderate cannabis use since the 80s. THC these days is way more potent!)

    Ginger on
  • I’m trying to be helpful; there are at least two grammar issues you might like to correct:

    “This is true for a number of processes in cannabis, it isn’t boat, …” Do you mean “a” boat? The spelling of “they’re.” “I tell my daughter their adult vitamins…”
    As to the substance of the article: 660 cases in the last 7 months IS an alarming stat if not put into context of % of all estimated cannabis sales for the same 7 mo. period for the same sector. Is the risk 10% or 0.00001%? Just stating it appears “minor and transient” is not persuasive, especially when this is easily determined. It seems dismissive in an otherwise well-written rebuttal.
    Terry on

Leave a comment

Please note, comments must be approved before they are published